Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 12;306(14):1593-4.
doi: 10.1001/jama.2011.1459.

A model for dissemination and independent analysis of industry data

Harlan M Krumholz  1 , Joseph S Ross
Affiliations

A model for dissemination and independent analysis of industry data

Harlan M Krumholz et al. JAMA. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Krumholz chairs a cardiac scientific advisory board for UnitedHealth. Dr. Ross is a member of a scientific advisory board for FAIR Health, Inc.

Figures

Figure
Figure
Model for Dissemination and Independent Analysis of Industry Data.
See this image and copyright information in PMC

References

    1. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010;341:c4737. - PMC - PubMed
    1. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med. 2009 Sep;6(9) e1000144. - PMC - PubMed
    1. Marciniak TA. Memorandum: Cardiovascular events in RECORD, NDA 21-071/S035. [Accessed September 7, 2011];FDA briefing document, advisory committee meeting for NDA 21071 Avandia (rosiglitazone maleate) table. 2010 Jun 14; www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrin....
    1. Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med. 2010;170(22):2035–2036. - PMC - PubMed
    1. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005;5:14. - PMC - PubMed

Publication types